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Background: The Ouabain and Adducin for Specific Intervention on Sodium in Hypertension (OASIS-HT) Trial was
a phase-2 dose-finding study of rostafuroxin, a digitoxygenin derivative, which selectively antagonizes the effects of
endogenous ouabain (EO) on Na
+,K
+-ATPase and mutated adducin. Rostafuroxin lowered blood pressure (BP) in
some animal models and in humans.
Methods: OASIS-HT consisted of 5 concurrently running double-blind cross-over studies. After 4 weeks without
treatment, 435 patients with uncomplicated systolic hypertension (140-169 mm Hg) were randomized to
rostafuroxin (0.05, 0.15, 0.5, 1.5 or 5.0 mg/d) or matching placebo, each treatment period lasting 5 weeks. The
primary endpoint was the reduction in systolic office BP. Among the secondary endpoints were diastolic office BP,
24-h ambulatory BP, plasma EO concentration and renin activity, 24-h urinary sodium and aldosterone excretion,
and safety. ANOVA considered treatment sequence (fixed effect), subjects nested within sequence (random), period
(fixed), and treatment (fixed).
Results: Among 410 analyzable patients (40.5% women; mean age, 48.4 years), the differences in the primary
endpoint (rostafuroxin minus placebo) ranged from -0.18 mm Hg (P = 0.90) on 0.15 mg/d rostafuroxin to 2.72 mm
Hg (P = 0.04) on 0.05 mg/d. In the 5 dosage arms combined, the treatment effects averaged 1.30 mm Hg (P = 0.03)
for systolic office BP; 0.70 mm Hg (P = 0.08) for diastolic office BP; 0.36 mm Hg (P = 0.49) for 24-h systolic BP; and
0.05 mm Hg (P = 0.88) for 24-h diastolic BP. In the 2 treatment groups combined, systolic (-1.36 mm Hg) and diastolic
(-0.97 mm Hg) office BPs decreased from week 5 to 10 (P for period effect ≤0.028), but carry-over effects were not
significant (P ≥ 0.11). All other endpoints were not different on rostafuroxin and placebo. Minor side-effects occurred
with similarly low frequency on rostafuroxin and placebo.
Conclusions: In 5 concurrently running double-blind cross-over studies rostafuroxin did not reduce BP at any dose.
Trial Registration: ClinicalTrials (NCT): NCT00415038
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Rostafuroxin (17b-[3-furyl]-5b-androstan-3b,14b,17a-triol;
PST2238) is a digitoxygenin derivative (Figure 1), which
selectively displaces ouabain from the Na
+,K
+-ATPase
receptor [1,2]. Rostafuroxin has been developed in an
attempt to unravel the contribution of mutated adducin
and endogenous ouabain in the pathogenesis of hyperten-
sion [3]. The compound lowered blood pressure in Milan
hypertensive rats and humans [4]. The Ouabain and
Adducin for Specific Intervention on Sodium in Hyperten-
sion (OASIS-HT) Trial is a phase-2 dose finding study,
which has been conducted at multiple centers in Europe
[3]. The primary objective of this double-blind trial was to
identify the minimal daily dose at which rostafuroxin in
patients with uncomplicated hypertension would reduce
blood pressure significantly more than placebo. The pre-
sent paper summarizes the effects of rostafuroxin on
blood pressure and sodium homeostasis and reports on
drug safety.
Methods
Overview of the design of the trial
The protocol of the OASIS-HT trial (registration num-
ber http://clinicaltrial.gov, NCT00415038) has been pub-
lished in detail elsewhere [3]. OASIS-HT was conducted
according to rules of good clinical practice [5] at 39
European centers, which all received approval from the
competent Ethics Committees and the National Regula-
tory Authorities. OASIS-HT was an early phase-2 dose-
finding study (Figure 2). After a run-in period of
4 weeks, eligible patients were randomized to one of
5 oral doses of rostafuroxin (0.05, 0.15, 0.5, 1.5 or
5.0 mg/d). Each dose was compared to placebo in a dou-
ble-blind cross-over experiment with balanced randomiza-
tion. Treatment was initiated with the active drug and
continued with placebo or vice versa. Each double-blind
period lasted 5 weeks with an intermediate visit at 2 weeks
and a final visit 3 weeks later. OASIS-HT was therefore a
combination of 5 concurrent cross-over studies, one for
each dose of rostafuroxin to be studied (Figure 2). The
total duration of the study, including the 4-week run-in
period, was 14 weeks. The wide range of doses used in
OASIS-HT was based on preclinical studies that showed
rostafuroxin inhibited ouabain-mediated actions at doses
or concentrations that were approximately 10-fold lower
than those required for antagonizing the effects of mutated
adducin [2,6].
Inclusion and exclusion criteria
Women and men, aged 30-59 years, with stage I or II
hypertension according to the 2003 European guidelines
[7] without any associated complications were eligible.
At the screening visit, they had to be untreated or on
treatment with only one drug or a single fixed combina-
tion tablet containing no more than 2 antihypertensive
agents. At the screening visit, systolic blood pressure
had to range from 140 to 169 mm Hg, irrespective of
treatment status. At screening, patients gave written
informed consent and those on treatment had their anti-
hypertensive drugs discontinued. Two weeks later, while
the patients were untreated, their systolic blood pressure
h a dt or e m a i na b o v e1 4 0m mH g .A tt h ee n do ft h e
run-in period, 4 weeks after the screening visit, the
untreated systolic blood pressure had to range from 140
to 169 mm Hg. In addition to hypertension, patients
had to have less than 3 other risk factors, as defined by
the European guidelines [7]. Women with childbearing
potential had to apply an adequate contraceptive
technique.
The exclusion criteria included a 24-h urinary Na
+
excretion exceeding 200 mmol at the end of the run-in
period, malignant or secondary hypertension, distur-
bances of cardiac rhythm or conductance, electrocardio-
graphic evidence of left ventricular hypertrophy, a
history of myocardial infarction within 6 months of ran-
domization, heart disease requiring treatment, a serum
creatinine concentration higher than 1.3 mg/dL, micro-
albuminuria, gastrointestinal diseases which might influ-
ence the absorption or hepatic clearance of rostafuroxin,
overt or medically-treated diabetes, a body mass index
exceeding 30 kg/m
2, mental disorders, and substance
abuse.
Randomization
Randomization followed a balanced incomplete block
design. Each center was randomly allocated to one or
more incomplete blocks. Within blocks, patients were
randomly assigned to 4 or 6 of the 10 possible
sequences of rostafuroxin (5 doses) and placebo (either
preceding or following the active drug). A computerized
procedure generating random numbers was used for
randomization. Centers opted whether they would use
blocks of study medication for 4 or 6 patients. At the
end of the run-in period, the study manager at the coor-
dinating office (Leuven, Belgium) checked all entry and
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Figure 1 Chemical structure of rostafuroxin and ouabain.
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domized eligible patients to one of 5 doses of rostafur-
oxin (Figure 2). The first patient was randomized on
April 6, 2005, and the last on March 20, 2007.
Treatment
During the run-in period, the investigators informed
patients on the life style changes to be implemented,
including cessation of smoking, moderation of excessive
alcohol intake, regular physical activity, weight reduction
in overweight patients, and a reduction of dietary
sodium intake to 120-160 mmol/d. A 24-h urinary
sodium excretion at the end of the run-in period
exceeding 200 mmol was an exclusion criterion. After
randomization, in a cross-over design, patients took one
of the 5 doses or rostafuroxin or matching placebo for
5 weeks and during the next 5 weeks switched to the
alternative study medication. Short visits were scheduled
2 weeks after the initiation of each course of double-
blind medication and visits with an extensive evaluation
took place 3 weeks later at the end of each double-blind
treatment period.
Uncontrolled hypertension was a blood pressure of at
least 180 mm Hg systolic or 110 mm Hg diastolic on
office measurement, confirmed within one week after
the initial measurement. Patients with uncontrolled
hypertension during the first treatment period were
immediately withdrawn. Orthostatic hypotension was a
drop in systolic blood pressure by at least 40 mm Hg on
standing up from a sitting position. Patients experien-
cing orthostatic hypertension during the first treatment
period were crossed over to the second treatment per-
iod. Patients with uncontrolled hypertension or ortho-
static hypotension during the second treatment period
proceeded immediately to the end-of-study evaluation.
Patients took their study medication around 8 AM
before breakfast. Clinic visits were scheduled within
8 hours of drug intake. Depending on local conditions,
each center standardized the time interval between the
intake of the study medication and the measurement of
t h ec l i n i cb l o o dp r e s s u r e .O n the days before the end-
of-period visits 5 and 7 (Figure 2), the patients fasted
overnight. On these days, they took their study medica-
tion at the examination center after blood sampling and
shortly before the start of the ambulatory blood pressure
recording and the 24-h urine collection. Patients
returned unused capsules at each visit.
Blood pressure measurement
At the screening visit, the investigator determined the
appropriate cuff size for each patient. If arm circumfer-
ence was less than 32 cm, a standard cuff with a bladder
of 12 × 22 cm was applied. For arms with larger circum-
ference, cuffs had a bladder size of 15 × 31 cm. If at the
screening visit, the differences in systolic and diastolic
blood pressures between both arms were less than
10 mm Hg, all blood pressure readings throughout the
trial were obtained at the non-dominant arm. Otherwise,
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Figure 2 Diagrammatic representation of the protocol. Numbers indicate patients projected to be enrolled.
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Page 3 of 14the arm giving the highest blood pressure readings was
used.
At each visit, after the patients had rested for 5 minutes
in the sitting position, the observer measured the office
blood pressure 5 times consecutively at the brachial
artery, using the validated oscillometric Omron 705IT
recorder (Omron Healthcare Europe BV, Nieuwegein,
The Netherlands). The average of the last 3 readings was
used to determine eligibility and for statistical analysis.
Immediately after the 5 blood pressure measurements
with the patient in the sitting position, the observer
obtained 2 blood pressure readings while the patient was
standing. These 2 standing measurements were averaged
to determine the occurrence of orthostatic hypotension.
Throughout the trial, each patient was followed up using
the same Omron 705IT device applied to the same arm
by means of equally sized cuffs. To detect irregularities,
the quality of the blood pressure readings was monitored
during the study with respect to digit and number prefer-
ence [8].
At the end of the run-in period as well as at the end
of the 2 double-blind treatment periods, patients
underwent 24-h ambulatory blood pressure monitoring.
Validated oscillometric SpaceLabs 90207 recorders
(SpaceLabs Inc, Redmond, WA [9]) were programmed
to obtain blood pressure readings at 15-minute intervals
from 8 AM to 10 PM and at 30-minute intervals other-
wise. Daytime and night-time were defined on the basis
of the short fixed clock-time method [10] with intervals
ranging from 10 AM to 8 PM and from midnight to
6 AM, respectively. Intra-individual means of the ambu-
latory measurements were weighted by the time interval
between successive readings [11].
Other measurements
Venous blood was collected at baseline and at the end
of each treatment period. Immediately after blood sam-
pling, the patient provided a fresh urine specimen, took
the study medication and started a 24-h urine collection.
Daytime and night-time urines were collected in sepa-
rate containers. In addition to the routine hematological
and biochemical measurements for safety, measurements
included plasma renin activity, the plasma concentration
of endogenous ouabain, the 24-h urinary excretion of
sodium, potassium, aldosterone and creatinine, and
semi-quantitative dipstick tests on a fresh urine sample.
Plasma renin activity, plasma ouabain and urinary aldos-
terone were measured centrally at the Divisione di
Nefrologia Dialisi e Ipertensione, Ospedale San Raffaele
(Milan, Italy). At baseline and at the end of each treat-
ment period, patients also underwent a standard 12-lead
ECG recording.
Statistical analyses
The primary efficacy measure was the sitting systolic
blood pressure measured at the office. With significance
set at 5% and power at 90%, approximately 440 patients,
88 in each crossover arm, had to be randomized to
detect within each arm of the trial a blood pressure dif-
ference of 8 mm Hg between rostafuroxin and placebo,
assuming a standard deviation of 15 mm Hg and a
drop-out rate of 10%.
Statistical analyses were performed according to the
intention-to-treat principle with SAS software, version
9.2 (SAS Institute Inc, Cary, NC). The analysis set
included all patients who had at least one evaluation
available for each of the 2 cross-over periods. In case of
missing data, the last observation within each period
was carried forward. Patients who withdrew from the
study during the first treatment period because of
uncontrolled hypertension contributed to the statistical
analysis with the last blood pressure for the first period;
for the second period they were assigned the average
blood pressure on the treatment, which they should
have taken during the second period.
Measurements with a skewed distribution were nor-
malized by a logarithmic transformation. Sodium and
potassium excretions were standardized to 24 hours.
The effects of rostafuroxin on blood pressure and other
measurements were evaluated using analysis of variance
with the treatment sequence (fixed effect), subjects
nested within sequence (random effect), period (fixed
effect) and treatment (fixed effect) entered as covari-
ables. Measurements obtained at the end of each treat-
ment period were used as dependent variables. Analyses
were performed in each dosage arm separately and in all
dosage arms combined. The hypothesis of no sequence
effect in the ANOVA model was tested to check for
carry-over effects. In sensitivity analyses, we analyzed
the blood pressure changes from baseline to week 5,
using Student’s t-test for paired and unpaired observa-
tions. We also adjusted the ANOVA for 24-h urinary
sodium excretion and did a separate analysis in patients
whose 24-h urinary sodium excretion was less than
200 mmol at both weeks 5 and 10.
Results
Subject characteristics
Of the 642 screened patients, 435 (67.8%) met the entry
criteria and were randomized. Twenty-five patients were
not included in the analysis because they prematurely
terminated the trial in the first treatment period
(Figure 3). The reasons for premature termination were
withdrawal of consent (n = 16), adverse events other than
uncontrolled hypertension (n = 4), intake of concomitant
medication prohibited by the protocol (n = 3), loss to
follow-up (n = 1), and undocumented reasons (n = 1).
The baseline characteristics of the 166 women and
244 men included in the present analysis were similar
among all dosage and treatment arms (Table 1) with the
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Page 4 of 14exception of sitting diastolic blood pressure, which was
1.9 mm Hg lower (92.0 vs 93.9 mm Hg; P = 0.011;
Figure 4) in the placebo-to-active arm (n = 203) as com-
pared to the active-to-placebo arm (n = 207). Mean age
(± SD) was 48.4 ± 7.9 years. Conventional blood pres-
sure averaged 150.4 ± 7.6 mm Hg systolic and 93.0 ±
7.3 mm Hg diastolic. For the 24-h blood pressure, these
values were 137.3 ± 10.9 mm Hg and 85.8 ± 8.1 mm
Hg, respectively. Seventy-two (17.6%) patients were cur-
rent smokers and 203 (49.5%) reported alcohol intake.
Blood pressure
The conventional systolic and diastolic blood pressures
decreased (P ≤ 0.0001) on average by 5.3 ± 12.0 mm
Hg and 2.9 ± 8.1 mm Hg from baseline to week 5
(Figure 4). For the 24-h ambulatory systolic and diasto-
lic blood pressures, these reductions averaged 1.5 ± 10.5
mm Hg (P = 0.0056) and 1.5 ± 6.6 mm Hg (P ≤
0.0001), respectively. However, in each of the 5 dosage
arms, blood pressures were similar on rostafuroxin as
compared to placebo (Tables 2 and 3). The between-
treatment differences in the primary endpoint (active
minus placebo treatment) ranged from -0.18 mm Hg
(95% confidence interval [CI], -3.21 to 2.85; P = 0.90) on
0.15 mg/d rostafuroxin to 2.72 mm Hg (CI, 0.07 to 5.36;
P = 0.04) on 0.05 mg/d (Table 2). In the 5 dosage arms
combined, the between-treatment differences averaged
1.30 mm Hg (CI, 0.10 to 2.50; P = 0.03) for the systolic
office blood pressure; 0.70 mm Hg (CI, -0.09 to 1.50;
P = 0.08) for the diastolic office blood pressure; 0.36 mm
Hg (CI, -0.67 to 1.38; P = 0.49) for the systolic 24-h
blood pressure; and 0.05 mm Hg (CI, -0.61 to 0.72; P =
0.88) for the diastolic 24-h blood pressure. Similar results
were obtained when the day- and night-time blood pres-
sures were analyzed separately. No significant (P ≥ 0.11)
carry-over effect was detected in any of the dosage arms
for any of the blood pressure endpoints. In the 2 treat-
ment groups combined, the conventional systolic (-1.36
± 12.4 mm Hg) and diastolic (-0.97 ± 8.3 mm Hg) blood
pressures decreased slightly from week 5 to week 10,
leading to a significant period effect (P = 0.028 and P =
0.018 respectively).
Screened
(n=642)
Randomized
(n=435)
Completed
(n=393)
Premature termination during first  
treatment period for reasons 
other than uncontrolled 
hypertension (n=25)
Premature termination during first 
treatment period because of 
uncontrolled hypertension (n=7) 
Premature termination during 
second treatment period (n=10)
Intention-to-treat 
analysis (n=410)
Figure 3 Trial profile.
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Page 5 of 14Excretion of electrolytes
At baseline urinary volume averaged 1502 ± 574 mL/
24 h and the urinary sodium and potassium excretion
152.8 ± 55.7 mmol/24 h and 62.7 ± 35.2 mmol/24 h,
respectively. The sodium and potassium excretion rates
were greater (P ≤ 0.001) in daytime (115.0 ± 50.1
μmol/min and 50.3 ± 31.5 μmol/min) than nighttime
urine collections (90.7 ± 52.3 μmol/min and 30.8 ±
26.1 μmol/min). Both the daytime (+12.6 ± 88.0 μmol/
min; P = 0.0051) and nighttime (+17.4 ± 73.1 μmol/
min; P < 0.0001) sodium excretion rates, but not the
potassium excretion rates, increased significantly from
baseline to week 5, but thereafter remained unchanged
(P ≥ 0.11).
The 24-h, day- and nighttime excretion rates of
sodium and potassium were similar on placebo and
active treatment in all 5 dosage arms. The between-
treatment differences in the 5 dosage arms combined
averaged -5.1 μmol/min (CI, -10.5 to 0.4; P =0 . 0 7 1 )f o r
the 24-h sodium excretion and -0.2 μmol/min (CI, -2.6
to 2.2; P = 0.84) for the 24-h potassium excretion
(Table 4). Carry-over effects were not statistically signifi-
cant (P ≥ 0.55).
Plasma ouabain, plasma renin activity and urinary
aldosterone excretion
At baseline the geometric means of plasma ouabain,
plasma renin activity, and the urinary aldosterone excre-
tion were 164.3 pmol/L (CI, 57.1 to 472.5), 0.58 ng/mL/
h( C I ,0 . 1 2t o2 . 8 1 ) ,a n d2 6 . 3n m o l / 2 4h( C I ,4 . 6 3t o
150.1), respectively. These hormones did not change
during follow-up and were similar on placebo and rosta-
furoxin in each of the 5 dosage arms (Table 4). The
between-group ratios (active divided by placebo) in the
5d o s a g ea r m sc o m b i n e dw e r e1 . 0 4p m o l / L( C I ,0 . 9 8t o
1.10; N = 357; P = 0.192), 1.00 pmol/L (CI, 0.94 to 1.07;
N = 374; P = 0.95) and 0.99 (CI, 0.90 to 1.09; N = 334;
P = 0.86) for plasma ouabain, plasma renin activity and
Table 1 Baseline characteristics by dosage and treatment arm
Characteristic 0.05 mg/d 0.15 mg/d 0.5 mg/d 1.5 mg/d 5.0 mg/d
P/R
(N = 43)
R/P
(N = 44)
P/R
(N = 44)
R/P
(N = 44)
P/R
(N = 41)
R/P
(N = 44)
P/R
(N = 44)
R/P
(N = 44)
P/R
(N = 44)
R/P
(N = 43)
Mean (± SD) of baseline
characteristic
Age, years 48.1 ± 7.8 50.4 ± 7.4 46.8 ± 8.6 48.2 ± 8.0 48.8 ± 7.2 49.7 ± 7.5 49.0 ± 6.7 48.5 ± 8.5 49.7 ± 7.9 44.9 ± 8.4
BMI, kg/m
2 27.1 ± 2.7 27.6 ± 2.3 26.4 ± 2.7 26.9 ± 2.2 26.3 ± 2.7 27.0 ± 2.5 25.9 ± 3.0 26.9 ± 2.4 25.8 ± 2.5 26.7 ± 2.7
Pulse rate, beats/min 77.0 ±
10.8
77.6 ±
10.3
75.8 ±
12.8
74.4 ± 9.8 75.2 ±
11.0
76.8 ±
12.3
74.2 ±
11.8
80.5 ±
11.5
75.8 ±
13.0
77.3 ±
10.0
Systolic BP, mm Hg
Office 148.7 ±
7.3
150.9 ±
7.4
148.0 ±
5.8
150.5 ±
8.4
150.4 ±
7.6
152.5 ±
8.7
150.8 ±
7.6
151.1 ±
7.8
150.6 ±
6.7
149.4 ±
7.2
24-h ambulatory* 136.8 ±
9.5
137.3 ±
11.3
135.3 ±
10.4
134.9 ±
10.9
140.9 ±
11.0
137.4 ±
9.6
138.1 ±
11.2
137.8 ±
11.8
138.6 ±
11.4
136.2 ±
11.7
Daytime* 144.4 ±
9.9
143.7 ±
12.5
141.8 ±
10.4
142.3 ±
12.3
147.1 ±
12.7
142.9 ±
10.1
145.0 ±
13.6
144.5 ±
12.5
145.2 ±
12.6
142.2 ±
12.7
Night-time* 122.2 ±
11.9
123.5 ±
13.8
122.5 ±
14.8
119.9 ±
11.3
126.4 ±
12.2
125.6 ±
12.6
125.7 ±
11.7
123.5 ±
14.7
125.5 ±
13.0
122.8 ±
15.4
Diastolic BP, mm Hg
Office 92.1 ± 7.6 93.0 ± 7.0 91.9 ± 7.2 92.4 ± 7.2 92.3 ± 6.9 95.9 ± 7.2 92.0 ± 7.9 94.2 ± 8.2 92.8 ± 6.4 93.9 ± 6.5
24-h ambulatory* 85.5 ± 7.9 84.1 ± 7.2 84.5 ± 7.6 84.2 ± 8.4 88.1 ± 9.4 87.6 ± 8.8 86.5 ± 7.3 85.6 ± 8.4 86.9 ± 7.0 85.0 ± 9.0
Daytime* 91.6 ± 8.2 89.7 ± 8.8 90.2 ± 7.5 90.2 ± 9.5 93.2 ±
10.9
92.3 ± 9.1 91.5 ± 8.8 91.0 ± 8.8 92.5 ± 8.3 89.6 ±
10.0
Night-time* 73.4 ± 9.7 72.7 ± 8.4 74.3 ±
10.8
72.3 ± 7.8 77.1 ± 9.5 78.4 ±
10.8
77.1 ± 8.6 74.7 ±
11.0
76.6 ± 7.7 74.2 ±
10.5
Number (%) with baseline
characteristic
Women 20 (46.5) 18 (40.9) 21 (47.7) 15 (34.1) 12 (29.3) 14 (31.8) 21 (47.7) 16 (36.4) 22 (50.0) 18 (41.9)
Caucasian 43 (100) 44 (100) 44 (100) 44 (100) 41 (100) 42 (95.5) 43 (97.7) 43 (97.7) 44 (100) 43 (100)
Previous AH treatment 14 (32.6) 14 (31.8) 22 (50.0) 20 (45.5) 18 (43.9) 24 (54.5) 23 (52.3) 22 (50.0) 18 (40.9) 18 (41.9)
Current smokers 5 (11.6) 7 (15.9) 6 (13.6) 9 (20.5) 6 (14.6) 8 (18.2) 5 (11.4) 7 (15.9) 14 (31.8) 12 (27.9)
Current alcohol intake 21 (48.8) 23 (52.3) 19 (43.2) 23 (52.3) 22 (53.7) 21 (47.7) 18 (40.9) 23 (52.3) 20 (45.5) 27 (62.8)
Values are means ± SD or number (percentage) of patients. N indicates the number of patients. Abbreviations: P/R, 5 weeks placebo followed by 5 weeks
rostafuroxin; A/R, 5 weeks rostafuroxin followed by 5 weeks placebo; BP, blood pressure; AH, antihypertensive before the run-in period.
*Ambulatory blood pressure recordings were available in 383 patients.
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Page 6 of 14the 24-h urinary aldosterone excretion, respectively
(Table 4).
Safety
Among the 435 randomized patients, a total of 96
a d v e r s ee v e n t sw e r er e p o r t e do na c t i v et r e a t m e n ta n d
56 on placebo treatment. These events occurred in 64
and 50 patients, respectively (P = 0.14). Table 5 lists the
adverse events that occurred in at least 3 patients. The
following adverse events led to premature discontinua-
tion of the trial: uncontrolled hypertension (3 on pla-
cebo and 6 on rostafuroxin), fatal ruptured aortic
aneurysm (1 patient on placebo), metastatic cancer
(1 patient on placebo), loss of consciousness (1 patient
on rostafuroxin), increases in g-glutamyltransferase and
alkaline phosphatase activities (1 patient on placebo),
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Figure 4 Sitting systolic and diastolic blood pressures at randomization and at the end of each treatment period. Means and standard
errors are presented for the 5 dosage groups combined. Open circles indicate the patients receiving placebo during the first treatment period
and rostafuroxin during the second treatment period. Closed circles indicate the patients receiving rostafuroxin during the first treatment period
and placebo during the second treatment period.
Table 2 Office blood pressure on treatment with placebo or different daily doses of rostafuroxin
Mean level ± SD
at end of treatment period
Mean difference
(95% CI)
P-values
N Placebo Rostafuroxin Rostafuroxin minus
placebo
Treatment
effect
Carryover
effect
Period
effect
Systolic pressure, mm Hg
0.05 mg 83 142.0 ± 11.1 144.7 ± 12.2 2.72 (0.07 to 5.36) 0.044 0.352 0.229
0.15 mg 82 143.6 ± 13.5 143.3 ± 13.9 -0.18(-3.21 to 2.85) 0.905 0.897 0.364
0.5 mg 77 145.3 ± 13.8 145.9 ± 13.3 0.49 (-2.38 to 3.36) 0.732 0.326 0.770
1.5 mg 86 145.8 ± 13.7 146.8 ± 15.1 1.11 (-1.32 to 3.54) 0.366 0.828 0.723
5.0 mg 82 142.1 ± 12.1 144.5 ± 14.3 2.29 (-0.35 to 4.93) 0.089 0.667 0.038
All doses 410 143.7 ± 12.9 145.1 ± 13.8 1.30 (0.10 to 2.50) 0.034 0.963 0.028
Diastolic pressure, mm Hg
0.05 mg 83 88.1 ± 8.3 89.9 ± 9.2 1.76 (0.01 to 3.51) 0.049 0.846 0.639
0.15 mg 82 88.7 ± 9.1 88.5 ± 9.6 -0.25 (-2.03 to 1.54) 0.786 0.596 0.296
0.5 mg 77 90.6 ± 8.8 90.6 ± 8.2 0.02 (-1.92 to 1.95) 0.986 0.112 0.905
1.5 mg 86 90.5 ± 9.5 91.5 ± 8.9 0.98 (-0.65 to 2.61) 0.235 0.580 0.027
5.0 mg 82 88.4 ± 8.1 89.4 ± 8.5 0.97 (-1.01 to 2.95) 0.333 0.431 0.163
All doses 410 89.3 ± 8.8 90.0 ± 8.9 0.70 (-0.09 to 1.50) 0.084 0.364 0.018
Mean differences were estimated using analysis of variance with sequence, subjects nested within sequence, and period and treatment group entered as
covariables. Abbreviations: N = number of patients; SD, standard deviation; CI, confidence interval.
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Page 7 of 14nausea and bloated feeling (1 patient on placebo), and
cough and skin irritation (1 patient on rostafuroxin).
The hematological measurements and those reflecting
renal and liver function were similar at baseline and fol-
low-up (P ≥ 0.10) and none were different on placebo
and rostafuroxin (P ≥ 0.18) with one exception.
Hemoglobin was slightly lower on rostafuroxin than
placebo (8.99 vs 9.03 mmol/L; P = 0.049).
At baseline, heart rate averaged 76.2 ± 11.5 beats/min
on conventional measurement (sitting) and 74.5 ± 8.5
beats/min on 24-h ambulatory measurement. The base-
line values of the ECG intervals were 157.0 ± 24.9 msec,
Table 3 24-h ambulatory blood pressure on treatment with placebo and different daily doses of rostafuroxin
Mean level ± SD
at end of treatment period
Mean difference
(95% CI)
P-values
N Placebo Rostafuroxin Rostafuroxin
minus placebo
Treatment
effect
Carryover
effect
Period
effect
Systolic pressure, mm Hg
0.05 mg 79 133.1 ± 10.8 134.1 ± 11.2 0.99 (-1.42 to 3.40) 0.417 0.398 0.324
0.15 mg 76 134.8 ± 13.3 134.7 ± 12.0 -0.07 (-2.73 to 2.58) 0.957 0.348 0.166
0.5 mg 72 137.0 ± 10.7 137.0 ± 10.8 0.08 (-2.27 to 2.43) 0.945 0.790 0.889
1.5 mg 80 136.7 ± 13.1 137.8 ± 10.7 1.11 (-1.04 to 3.26) 0.306 0.753 0.741
5.0 mg 76 136.3 ± 11.8 135.9 ± 12.9 -0.36 (-2.37 to 1.64) 0.719 0.854 0.696
All doses 383 135.6 ± 12.0 135.9 ± 11.6 -0.36 (-0.67 to 1.38) 0.493 0.926 0.860
Diastolic pressure, mm Hg
0.05 mg 79 82.5 ± 8.3 83.2 ± 8.3 0.75 (-0.92 to 2.41) 0.374 0.611 0.446
0.15 mg 76 83.4 ± 9.0 83.1 ± 9.3 -0.29(-2.03 to 1.45) 0.743 0.467 0.155
0.5 mg 72 86.2 ± 8.4 85.2 ± 9.0 -1.01(-2.59 to 0.58) 0.210 0.459 0.630
1.5 mg 80 84.9 ± 9.3 85.4 ± 7.7 0.56 (-0.66 to 1.77) 0.365 0.900 0.559
5.0 mg 76 84.7 ± 8.5 84.8 ± 8.6 0.18 (-1.11 to 1.46) 0.785 0.687 0.677
All doses 383 84.3 ± 8.8 84.3 ± 8.6 0.05 (-0.61 to 0.72) 0.882 0.457 0.971
Mean differences were estimated using analysis of variance with sequence, subjects nested within sequence, and period and treatment group entered as
covariables. Abbreviations: CI, confidence interval; N = number of patients; SD, standard deviation.
Table 4 Urinary excretion rate of electrolytes, plasma ouabain concentration and plasma renin activity on placebo and
on rostafuroxin
Mean level
at the end of treatment period
Mean difference
(95% CI)
P-values
N Placebo Rostafuroxin Active minus
placebo
Treatment
effect
Carryover
effect
Period
effect
Sodium (μmol/min)
Whole day 386 122.3 ± 53.1 117.3 ± 50.4 -5.1 (-10.5 to 0.4) 0.071 0.546 0.256
Daytime 386 128.2 ± 69.8 126.3 ± 86.7 -1.9 (-10.9 to 7.0) 0.672 0.802 0.880
Nighttime 386 115.6 ± 87.4 107.6 ± 67.8 -8.0 (-16.4 to 0.4) 0.061 0.710 0.112
Potassium (μmol/min)
Whole day 386 43.7 ± 22.1 43.5 ± 20.2 -0.2 (-2.6 to 2.2) 0.844 0.942 0.685
Daytime 386 49.5 ± 29.1 50.7 ± 38.4 1.2 (-2.8 to 5.2) 0.545 0.641 0.320
Nighttime 386 33.4 ± 27.3 32.3 ± 21.8 -1.1 (-4.2 to 2.0) 0.479 0.692 0.775
Sodium/potassium ratio
Whole day 386 2.84 (0.99 to 7.74) 2.72 (0.96 to 8.13) 0.96 (0.90 to 1.01) 0.122 0.434 0.154
Daytime 386 2.64 (0.81 to 8.29) 2.53 (0.77 to 8.66) 0.96 (0.90 to 1.02) 0.196 0.490 0.273
Nighttime 386 3.46 (1.03 to 10.6) 3.34 (1.06 to 11.6) 0.97 (0.90 to 1.04) 0.327 0.093 0.314
Plasma ouabain (pmol/L) 357 155.4 (56.8 to 453) 161.6 (57.7 to 425.0) 1.04 (0.98 to 1.10) 0.192 0.997 0.369
Plasma renin activity (ng/mL/h) 374 0.57 (0.11 to 2.62) 0.57 (0.12 to 2.95) 1.00 (0.94 to 1.07) 0.948 0.087 0.672
Aldosterone excretion (nmol/24 h) 334 25.7 (5.96 to 130) 25.5(4.99 to 111) 0.99(0.90 to 1.09) 0.862 0.366 0.377
Mean levels at the end of the treatment period are arithmetic means ± SD or geometric means (95% confidence interval). Mean differences were estimated
using analysis of variance with sequence, subjects nested within sequence, and period and treatment group entered as covariables. Mean differences are
expressed as the difference of rostafuroxin minus placebo or the ratio of rostafuroxin to placebo for non-transformed and logarithmically transformed variables,
respectively. Abbreviations: CI, confidence interval; N = number of patients.
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Page 8 of 1485.3 ± 11.6 msec and 381.2 ± 40.8 msec, and 401.7 ±
52.5 msec for PR, QRS, QT and QTc, respectively. None
of these electrocardiographic measurements changed
during follow-up (P ≥ 0.77) and all were similar on
placebo and rostafuroxin (P ≥ 0.083).
Sensitivity analyses
There was a significant period effect with a slight, but
significant reduction in the conventional blood pressure
from week 5 until week 10 (see above). We therefore
did an additional analysis including only blood pressures
at baseline and at 5 weeks, according to a parallel-group
design based on the first randomization (Figure 2). The
results for the office and 24-h ambulatory blood pres-
sures appear in Tables 6 and 7. The results of this paral-
lel-group analysis confirmed those of the double-blind
cross-over analysis.
If the ANOVA model used for the cross-over analy-
sis of blood pressure was adjusted for 24-h sodium
excretion, the mean difference (rostafuroxin all doses
combined minus placebo) was 1.32 mm Hg (CI, 0.12
to 2.52; P = 0.03) for systolic office blood pressure and
0.68 (CI, -0.13 to 1.49; P = 0.10) for diastolic office
blood pressure. Furthermore, in the 199 patients with
24-h urinary sodium excretion below 200 mmol at
baseline and at 5 and 10 weeks, the corresponding esti-
mates were 0.88 mm Hg systolic (CI, -0.85 to 2.61; P =
0.18) and -0.39 mm Hg diastolic (CI, -1.53 to 0.75; P =
0.50). Finally, analyses of the office blood pressure
(Table 8) and the 24-h blood pressure (Table 9) in pre-
viously untreated patients were also in agreement with
the overall results of the trial, as shown in Tables 2
and 3, respectively.
Discussion
The primary objective of the double-blind OASIS HT
trial was to identify the minimal daily dose at which ros-
tafuroxin in patients with uncomplicated hypertension
w o u l dr e d u c eb l o o dp r e s s u r es i g n i f i c a n t l ym o r et h a n
placebo. The primary endpoint was the reduction in sys-
tolic blood pressure defined as the average of 3 office
readings with the patient in the sitting position. The key
finding was that rostafuroxin compared to placebo did
n o tr e d u c eb l o o dp r e s s u r ea ta n yd o s eo ra ta l ld o s e s
combined. Side-effects were rare and occurred with
similar frequencies on placebo and rostafuroxin.
Design of OASIS-HT
Phase 2 dose-finding trials commonly implement a paral-
lel-group design, in which patients are randomized to
incremental doses of the investigational drug and an
untreated control group. The European Project on Genes
in Hypertension [12-15] and several other studies [16,17]
demonstrated that phenotype-genotype relations depend
on host factors, such as sex and age, as well as on life-
style, in particular salt intake as reflected by the 24-h
urinary excretion of sodium. These reports highlighted
the concept that phenotype-genotype associations can
Table 5 Number of patients with adverse events on placebo and different daily doses of rostafuroxin
Placebo Rostafuroxin
All All 0.05 mg 0.15 mg 0.5 mg 1.5 mg 5.0 mg
Total number of patients 419* 419† 84 84 81 87 83
Number with complaints
Osteomuscular‡ 431 1 0 0 1
Gastro-intestinal# 5 5 0 1 1 1 2
Dizziness 2 5 0 1 0 4 0
Dry mouth 1 4 1 0 0 1 2
Headache 8 14 3 4 2 2 3
High blood pressure 4 6 1 3 2 0 0
Otitis 1 2 0 1 1 0 0
Palpitations 1 3 0 0 1 0 2
Cutaneous§ 0 4 2 1 0 1 0
Upper respiratory tract infections 5 8 5 1 0 0 2
Urinary abnormalities¶ 0 5 2 0 2 1 0
Urinary tract infections 2 5 1 2 0 2 0
Values are number of subjects.
*16 subjects did not receive placebo, because they withdrew from the trial in the first treatment period, while on rostafuroxin.
†16 subjects did not receive rostafuroxin, because they withdrew from the trial in the first treatment period, while on placebo.
‡Bursitis or pain in back, neck, knees, or shoulders.
#Distension, abdominal pain, dyspepsia, gastritis, gastroenteritis or nausea.
§Skin irritation, rash or dermatitis.
¶Proteinuria, glucosuria, or hematuria on semiquantitative dipstick test.
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Page 9 of 14Table 6 Office blood pressure at the end of the baseline period and at 5 weeks after randomization
Mean level ± SD
at end of period
Mean differences
(95% CI)
P-value
N Baseline 5 weeks 5 weeks minus
baseline
Double difference
(rostafuroxin minus placebo)
Systolic pressure, mm Hg
Placebo 203 149.8 ± 7.2 144.5 ± 12.5 -5.35 (-6.97 to -3.74)
Rostafuroxin
0.05 mg 42 150.5 ± 7.3 144.5 ± 12.6 -6.00 (-9.86 to -2.13) -1.20 (-6.28 to 3.87) 0.64
0.15 mg 40 150.5 ± 8.4 143.9 ± 12.4 -6.60 (-9.91 to -3.29) -3.08 (-8.03 to 1.88) 0.22
0.5 mg 40 153.0 ± 8.7 147.4 ± 11.5 -5.65 (-9.42 to -1.88) 0.96 (-4.74 to 6.66) 0.74
1.5 mg 43 151.0 ± 7.9 147.4 ± 15.2 -3.68 (-7.87 to 0.51) 1.59 (-3.77 to 6.95) 0.56
5.0 mg 42 149.6 ± 7.1 145.3 ± 14.0 -4.31 (-8.55 to -0.07) 2.45 (-3.05 to 7.95) 0.38
All doses 207 150.9 ± 7.9 145.7 ± 13.2 -5.22 (-6.92 to -3.53) 0.13 (-2.21 to 2.47) 0.91
Diastolic pressure, mm Hg
Placebo 203 92.0 ± 7.2 89.4 ± 8.7 -2.63 (-3.77 to -1.50)
Rostafuroxin
0.05 mg 42 92.9 ± 7.2 89.9 ± 8.3 -3.01 (-4.90 to -1.11) 0.52 (-2.65 to 3.70) 0.75
0.15 mg 40 92.3 ± 7.5 88.5 ± 8.5 -3.82 (-6.12 to -1.51) -1.94 (-5.52 to 1.65) 0.28
0.5 mg 40 95.9 ± 6.6 92.0 ± 7.8 -3.96 (-6.67 to -1.25) -1.20 (-5.32 to 2.92) 0.56
1.5 mg 43 94.2 ± 8.3 92.9 ± 9.4 -1.33 (-3.77 to 1.12) -0.21 (-3.26 to 2.84) 0.89
5.0 mg 42 94.0 ± 6.5 90.7 ± 9.2 -3.33 (-6.32 to -0.35) 0.68 (-3.15 to 4.51) 0.72
All doses 207 93.9 ± 7.3 90.8 ± 8.7 -3.06 (-4.15 to -1.98) -0.43 (-2.00 to 1.13) 0.59
Mean differences were estimated with a paired and unpaired t-tests for within-group and between-group differences, respectively. The double difference is the
net treatment effect defined as the difference placebo minus baseline subtracted from the difference rostafuroxin minus baseline (parallel-group analysis).
Abbreviations: N = number of patients; SD, standard deviation; CI, confidence interval.
Table 7 24-h ambulatory blood pressure at the end of the baseline period and at 5 weeks after randomization
Mean level ± SD
at end of period
Mean differences
(95% CI)
P-value
N Baseline 5 weeks 5 weeks minus
baseline
Double difference
(rostafuroxin minus placebo)
Systolic pressure, mm Hg
Placebo 189 137.8 ± 10.7 135.6 ± 12.2 -2.28 (-3.78 to -0.77)
Rostafuroxin
0.05 mg 39 137.3 ± 11.3 132.5 ± 11.2 -4.74 (-8.00 to -1.48) -1.16 (-5.38 to 3.06) 0.59
0.15 mg 36 134.9 ± 10.9 137.3 ± 11.2 +2.36 (-0.62 to 5.34) 3.16 (-1.32 to 7.63) 0.16
0.5 mg 38 137.4 ± 9.6 136.7 ± 9.9 -0.76 (-4.44 to 2.92) 2.63 (-2.44 to 7.70) 0.30
1.5 mg 40 137.8 ± 11.8 138.0 ± 10.3 +0.21 (-3.10 to 3.51) 2.12 (-2.74 to 6.98) 0.39
5.0 mg 36 136.2 ± 11.7 135.6 ± 11.9 -0.52 (-4.32 to 3.27) 1.33 (-4.00 to 6.66) 0.62
All doses 189 136.8 ± 11.0 136.0 ± 11.0 -0.74 (-2.24 to 0.77) 1.54 (-0.59 to 3.66) 0.16
Diastolic pressure, mm Hg
Placebo 189 86.2 ± 7.8 84.0 ± 8.7 -2.28 (-3.28 to -1.28)
Rostafuroxin
0.05 mg 39 84.1 ± 7.2 82.4 ± 8.4 -1.65 (-3.25 to -0.06) 1.62 (-0.74 to 3.97) 0.18
0.15 mg 36 84.2 ± 8.4 84.6 ± 9.1 +0.41 (-1.46 to 2.28) 1.62 (-1.23 to 4.47) 0.26
0.5 mg 38 87.6 ± 8.8 85.7 ± 8.3 -1.89 (-4.15 to 0.37) 0.68 (-2.65 to 4.01) 0.68
1.5 mg 40 85.6 ± 8.4 85.4 ± 7.4 -0.28 (-1.96 to 1.40) 1.64 (-1.21 to 4.50) 0.25
5.0 mg 36 85.0 ± 9.0 85.4 ± 8.4 +0.36 (-2.34 to 3.07) 2.85 (-0.86 to 6.57) 0.13
All doses 189 85.3 ± 8.4 84.7 ± 8.3 -0.63 (-1.52 to 0.26) 1.65 (0.31 to 2.98) 0.02
Mean differences were estimated with paired and unpaired t-tests for within-group and between-group differences, respectively. The double difference is the net
treatment effect defined as the difference placebo minus baseline subtracted from the difference rostafuroxin minus baseline (parallel-group analysis).
Abbreviations: N = number of patients; SD, standard deviation; CI, confidence interval.
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Page 10 of 14only be studied within a defined ecogenetic context.
Furthermore, previous population studies demonstrated
interaction between the plasma concentration of ouabain
and the 24-h urinary sodium excretion in relation to systo-
lic and diastolic blood pressures [18]. Cross-over studies
compared to parallel-group designs, and ambulatory moni-
toring compared to the office measurement of blood
pressure, reduce the variability in the estimated effects of
any antihypertensive intervention and therefore allow
economizing on sample size. These considerations explain
the design of the OASIS HT trial, which is a combination
of 5 concurrent cross-over studies, one for each dose of
rostafuroxin to be studied, and the use of ambulatory mon-
itoring to measure the secondary blood pressure endpoints.
Table 8 Office blood pressure on treatment with placebo or different daily doses of rostafuroxin in previously
untreated patients
Mean level ± SD
at end of treatment period
Mean difference
(95% CI)
P-values
N Placebo Rostafuroxin Rostafuroxin minus
placebo
Treatment
effect
Carryover
effect
Period
effect
Systolic pressure, mm Hg
0.05 mg 57 141.1 ± 11.8 145.8 ± 12.8 4.59 (1.43 to 7.74) 0.005 0.319 0.174
0.15 mg 41 140.3 ± 12.1 140.7 ± 13.8 0.26 (-4.10 to 4.61) 0.906 0.312 0.062
0.5 mg 38 142.1 ± 15.5 142.9 ± 13.4 0.72 (-4.01 to 5.45) 0.759 0.271 0.530
1.5 mg 41 140.9 ± 11.8 142.9 ± 12.6 2.02 (-1.46 to 5.51) 0.248 0.414 0.959
5.0 mg 48 139.1 ± 9.9 142.1 ± 12.9 2.89 (-0.54 to 6.31) 0.096 0.477 0.113
All doses 225 140.7 ± 12.1 143.0 ± 13.1 2.35 (0.71 to 4.00) 0.005 0.674 0.044
Diastolic pressure, mm Hg
0.05 mg 57 87.4 ± 8.4 89.2 ± 8.5 1.78 (-0.45 to 4.01) 0.115 0.951 0.417
0.15 mg 41 88.0 ± 8.5 88.3 ± 9.9 0.29 (-2.30 to 2.88) 0.823 0.836 0.252
0.5 mg 38 87.8 ± 8.6 88.6 ± 8.2 0.80 (-2.61 to 4.21) 0.636 0.112 0.873
1.5 mg 41 88.0 ± 8.9 90.8 ± 6.4 2.82 (0.51 to 5.12) 0.018 0.344 0.191
5.0 mg 48 86.7 ± 8.0 88.4 ± 7.8 1.74 (-1.17 to 4.66) 0.235 0.510 0.173
All doses 225 87.5 ± 8.4 89.1 ± 8.2 1.53 (0.37 to 2.69) 0.010 0.714 0.033
Mean differences were estimated using analysis of variance with sequence, subjects nested within sequence, and period and treatment group entered as
covariables. Abbreviations: N = number of patients; SD, standard deviation; CI, confidence interval.
Table 9 24-h ambulatory blood pressure on treatment with placebo and different daily doses of rostafuroxin in
previously untreated patients
Mean level ± SD
at end of treatment period
Mean difference
(95% CI)
P-values
N Placebo Rostafuroxin Rostafuroxin minus
placebo
Treatment
effect
Carryover
effect
Period
effect
Systolic pressure, mm Hg
0.05 mg 55 131.9 ± 10.7 133.9 ± 11.5 2.02 (-0.68 to 4.73) 0.139 0.129 0.282
0.15 mg 39 130.9 ± 10.7 131.5 ± 11.8 0.51 (-2.59 to 3.60) 0.743 0.179 0.588
0.5 mg 36 135.2 ± 9.5 135.2 ± 9.4 0.04 (-3.38 to 3.46) 0.981 0.523 0.815
1.5 mg 40 135.3 ± 14.0 137.7 ± 11.7 2.39 (-1.20 to 5.99) 0.185 0.975 0.193
5.0 mg 44 133.7 ± 10.5 133.0 ± 12.2 -0.68 (-3.72 to 2.36) 0.654 0.831 0.749
All doses 214 133.3 ± 11.2 134.2 ± 11.5 0.91 (-0.45 to 2.28) 0.188 0.598 0.911
Diastolic pressure, mm Hg
0.05 mg 55 80.4 ± 7.4 81.9 ± 7.8 1.53 (-0.22 to 3.28) 0.085 0.238 0.436
0.15 mg 39 81.9 ± 7.6 81.5 ± 8.1 -0.42(-2.80 to 1.97) 0.725 0.952 0.328
0.5 mg 36 85.6 ± 7.8 84.2 ± 9.1 -1.42(-3.77 to 0.94) 0.230 0.803 0.739
1.5 mg 40 82.5 ± 9.5 84.0 ± 7.7 1.52 (-0.42 to 3.47) 0.121 0.667 0.463
5.0 mg 44 82.4 ± 7.4 82.2 ± 6.9 -0.16 (-2.07 to 1.75) 0.867 0.719 0.927
All doses 214 82.4 ± 8.0 82.7 ± 7.9 0.32 (-0.57 to 1.22) 0.474 0.405 0.757
Mean differences were estimated using analysis of variance with sequence, subjects nested within sequence, and period and treatment group entered as
covariables. Abbreviations: CI, confidence interval; N = number of patients; SD, standard deviation.
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agent
In placebo-controlled phase-1 studies in healthy male
volunteers (Sigma Tau, data on file), who received rosta-
furoxin in a daily dose ranging from 1 to 10 mg for up
to 7 days, no clinically significant adverse effects
occurred [4,6,19]. In particular, as in the present study,
the compound had no influence on electrocardiographic
measurements, including the RR, PR, QRS, QT and QTc
intervals. After the initial dose, a few volunteers in the
active-treatment and placebo groups had mild com-
plaints, mainly headache, which all subsided unevent-
fully. Because of glucuronide hydrolysis, the parent
compound was undetectable in urine, but the excretion
of the urinary metabolite (PST2490) linearly increased
with the orally administered dose.
In an uncontrolled phase-2 pilot study with forced
titration, never-treated hypertensive patients received
rostafuroxin during 3 sequential periods of 1 month in
daily doses of 0.1 mg, 1 mg, and 5 mg, respectively
(Sigma Tau, data on file [4]). Compared to baseline, the
decreases in mean arterial pressure averaged 3.0 mm Hg
(P = 0.039), 5.0 mm Hg (P = 0.007), and 5.0 mm Hg
(P = 0.014), respectively. In a second study with double-
blind design (Sigma Tau, data on file [4]), 42 and 21
patients with uncomplicated hypertension were rando-
mized to 12 weeks of treatment with either rostafuroxin
0.5 mg/d or losartan 50 mg/d. The intention-to-treat
analysis showed that at the end of follow-up blood pres-
sure was slightly higher on rostafuroxin than losartan,
but that the proportion of patients whose diastolic
blood pressure dropped to 90 mm Hg or less was 38.0%
in the 2 groups. Of the 42 patients randomized to rosta-
furoxin, 38 showed a decrease in systolic blood pressure
[4]. All of these 38 patients had a sodium excretion
below 210 mmol per day [4]. Whether salt intake
explains the contradiction between this previous and the
current study cannot be established with certainty. In
the previous study (Sigma Tau, data on file [4]), mild
adverse events were equally frequent (19.0%) on rosta-
furoxin and losartan, and with the exception of one case
of gastritis on rostafuroxin, they were all considered to
be unrelated to treatment. In agreement with these pre-
vious observations, the present study did not reveal any
serious drug-related adverse event.
Interpretation of the current results
In the present dose-finding study, rostafuroxin at any
dose or at all doses combined did not lower blood pres-
sure. In fact, compared with placebo, the office systolic
blood pressure increased by 1.30 mmHg (P =0 . 0 3 4 )i n
all patients on rostafuroxin and by 2.72 mm Hg (P =
0.044) in those randomized to 0.05 mg/d. Several
mechanisms might explain these negative findings. First,
the large drop in blood pressure between baseline and
the end of the first double-blind period (Figure 4) and
the slight but significant period effect in the office blood
pressure might have concealed a real antihypertensive
effect of rostafuroxin. We therefore did an alternative
analysis based on the first randomization to parallel
groups. The results of this parallel-group analysis, in
which we compared the blood pressure changes on pla-
cebo and on active medication from baseline to week 5,
confirmed the double-blind cross-over analysis.
Second, previous studies demonstrated that the blood
pressure lowering action of 0.5 mg/d of rostafuroxin
occurred only at a 24-h urinary sodium excretion below
210 mmol. Sodium excretion at baseline averaged 152.8
± 55.7 mmol/24 h (5-95th percentile interval, 69.4 to
221.0) and subsequently increased to 170.2 ± 74.4
mmol/24 h (5-95th percentile interval, 71.6 to 314.0) at
5 weeks and to 174.8 ± 73.8 mmol/24 h (5-95th percen-
tile interval, 71.2 to 295.6) at 10 weeks. A 24-h urinary
sodium excretion below 200 mmol was a positive selec-
tion criterion at the end of the run-in period [3]. How-
ever, of 386 analyzable patients, only 199 (51.6%)
maintained a 24-h urinary sodium excretion below this
threshold at both 5 and 10 weeks. Sensitivity analyses,
in which the office blood pressure was adjusted for the
24-h urinary sodium excretion, or which were limited to
patients with a 24-h urinary sodium excretion below
200 mmol throughout the study, confirmed the main
results given in Table 2.
Finally, of the 410 analyzed patents, 193 (47.1%) had
been previously treated for hypertension. Antihyperten-
sive treatment potentially conceals the effects of
mutated adducin and ouabain on blood pressure. A
4-week period was probably insufficient to wash-out all
effects of prior treatment. However, for reasons of
recruitment, it proved impossible to limit the recruit-
ment to never-treated patients, as we did before [20].
For ethical reasons, we could not extend the wash-out
beyond 4 weeks. However, sensitivity analyses in never
treated patients also confirmed the main results pre-
sented in Tables 2 and 3.
Conclusion
Rostafuroxin did not reduce blood pressure at any dose.
Important secondary objectives of the OASIS-HT trial
were to investigate the dependence of the blood pressure
lowering activity of rostafuroxin on genetic variation in
the enzymes involved in the synthesis and breakdown of
ouabain and on polymorphisms in the adducin cytoskele-
ton proteins. The results of these analyses are beyond the
scope of this report and will be reported elsewhere. In
short, the pharmacogenomic study revealed that carriers
of a genetic profile stated ap r i o r iand representing
23% of the patients randomized in OASIS-HT showed
Staessen et al. Trials 2011, 12:13
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Page 12 of 14a significant decrease in blood pressure. Based on these
preliminary pharmacogenomic results, we are now starting
a more focused phase-2 trial comparing the effects of ros-
tafuroxin and losartan in hypertensive patients with a spe-
cific genetic profile (EudraCT Number 2010-022073-34).
Appendix
Participating centers
Belgium―H Celis (Leuven); The Czech Republic―R Cifková
(Prague), J Filipovský (Pilsen), J Peleška, J Widimský Jr
(Prague), M Souček, J Vítovec (Brno), J Špinar (Brno),
V Stanek J Widimský Sr (Prague); France―A Fournier
(Amiens); Germany―E Brand, SM Brand-Herrmann
(Münster); Ireland―J .B a r t o n ,C .K e l l y( G a l w a y ) ;Italy
―G Basso (Schio), E Casiglia, V Tikhonoff (Padua), G
Colangeli (Castelfranco), E Degli Esposti (Ravenna),
N Glorioso (Sassari), P Manunta (Milan), M Timio
(Foligno); The Netherlands―PW de Leeuw (Maastricht),
M Krekels (Sittard); Poland―MD łuzniewski (Warsaw),
T Grodzicki (Krakow), A Januszewicz (Warsaw),
K Kawecka-Jaszcz, A Olszanecka, K Stolarz-Skrzypek,
M Klocek (Krakow), K Narkiewicz, B Wyrzykowski
(Gdansk), W Piwowarska (Krakow), A Tykarski (Poznan);
The Russian Federation―Y Nikitin (Novosibirsk),
V. Milyagin (Smolensk), S. Nedogoda (Volgograd);
Slovenia―J Brugljan, R Acceto (Ljubljana); Spain―
P Armario (Barcelona), C Calvo-Gomez (Santiago de
Compostela), JA Division-Garrote (Salud), A Coca-
Payeras (Barcelona), F Hernández-Menárgez (Murcia),
M Luque-Otero (Madrid), M Pascual-Izuel (Sagunto),
A Pose-Reino (Santiago de Compostela), J Redón (Valencia);
Switzerland―MB u r n i e r .
Coordination
Scientific Coordinators―J A Staessen, G Bianchi; National
Coordinators―R Acceto (Slovenia), G Bianchi (Italy),
E Brand (Germany), M Burnier (Switzerland), H Celis
(Belgium); J Filipovský (Czech Republic), A Fournier
(France), K Kawecka-Jaszcz (Poland), G McInnes (United
Kingdom), Y Nikitin (Russian Federation), ET O’Brien
(Ireland), J Redón (Spain); Studies Coordinating Office―T
Kuznetsova, Y Jin, T Richart, JA Staessen, L Thijs (Leuven,
Belgium); Logistic Coordination―A Bacchieri, G Valentini
(Pomezia, Italy).
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